enGene Therapeutics ENGN
NASDAQ ENGN
$2.41 +0.13 (+5.70%)
At close: Nov 13, 2026 · 4:00 PM EST

enGene Therapeutics (ENGN) Total Non-Current Liabilities (2022)

Updated

enGene Therapeutics (ENGN) posted Total Non-Current Liabilities of $89.07 million for fiscal Q4 2022 (quarter ended Oct 31, 2022).

Analysis

enGene Therapeutics (ENGN) Total Non-Current Liabilities (2022) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Eli Lilly 1,359.75 Bn 1,333.37 Bn 20.46 Bn 60.81 Bn
2 Johnson & Johnson 688.76 Bn 608.62 Bn 17.30 Bn 102.65 Bn
3 AbbVie 521.69 Bn 489.75 Bn 13.12 Bn 117.60 Bn
4 Merck 364.31 Bn 327.31 Bn 13.19 Bn 79.95 Bn
5 Novartis Ag 306.35 Bn 279.93 Bn - -
6 Astrazeneca 285.96 Bn 259.56 Bn 13.26 Bn -36.84 Bn
7 Amgen 251.88 Bn 203.53 Bn 7.58 Bn 76.12 Bn
8 Gilead Sciences 208.59 Bn 183.61 Bn 6.73 Bn 36.05 Bn
9 Pfizer 164.73 Bn 112.38 Bn 12.56 Bn 96.04 Bn
10 enGene Therapeutics 161.50 Mn -832.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Oct 31, 2022 89.07 Mn
API Access

enGene Therapeutics Total Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-non-current-liabilities&ticker=ENGN&period=max&api_key=YOUR_API_KEY